secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001682852-22-000020
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q1 revenue $6.1B, net income $3.7B; reiterates $21B 2022 APAs
---------------------------------------------------------------------

- GAAP diluted EPS of $8.58 vs $2.84 YoY; revenue tripled to $6.1B from $1.9B.
- Cost of sales 17% of product sales; R&D $554M, SG&A $268M.
- Cash, equivalents, and investments $19.3B at quarter end; operating cash flow $2.8B.
- Four programs in Phase 3 in Q2: Omicron bivalent COVID booster, flu, RSV, CMV.
- CFO David Meline retiring; Jorge Gomez appointed CFO effective May 9, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285222000020/0001682852-22-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285222000020/mrna-20220504.htm
  HTML page:      https://secwatch.observer/filing/0001682852-22-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer